Drug Profile
Research programme: microRNA therapeutics - Microlin Bio
Alternative Names: Colomiralin™; Lumiralin™; miR 17 5p inhibitor - Microlin Bio; miR 17 inhibitors - Microlin Bio; miR 21 inhibitor - Microlin Bio; miR 484 inhibitor - Microlin Bio; Omiralin™; Promiralin™Latest Information Update: 28 Oct 2019
Price :
$50
*
At a glance
- Originator Ohio State University
- Developer Microlin Bio; Ohio State University
- Class Antisense oligonucleotides; MicroRNAs; Oligonucleotides
- Mechanism of Action MicroRNA inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Lung cancer
Most Recent Events
- 28 Oct 2019 No recent reports of development identified for preclinical development in Lung-cancer in USA (IV)
- 12 Jan 2016 Preclinical data released by Microlin Bio
- 24 Sep 2015 Research programme: microRNA therapeutics - Microlin Bio is available for licensing as of 24 Sep 2015. http://www.microlinbio.com/